

# company announcement

## Trading in Novo Nordisk shares by board members, executives and associated persons

**Bagsværd, Denmark, 8 February 2024** — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

<b>Details of the person discharging managerial responsibilities/person closely associated</b>		
a)	Name of the Board member/Executive/Associated Person	Karsten Munk Knudsen
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
<b>3</b>	<b>Details of the issuer</b>	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
<b>4</b>	<b>Details of the transaction(s)</b>	

a)	Description of the financial instrument, type of instrument, Identification code	Shares  Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 800.98</td> <td>60,000 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 800.98	60,000 shares		
Price(s)	Volume(s)							
DKK 800.98	60,000 shares							
d)	Aggregated information <ul style="list-style-type: none"> <li>Aggregated volume</li> <li>Price</li> </ul>	60,000 shares DKK 800.98						
e)	Date of the transaction	2024-02-07						
f)	Place of the transaction	Nasdaq Copenhagen						

*Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](https://www.novonordisk.com), [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).*

## Contacts for further information

### Media:

**Ambre James-Brown**

+45 3079 9289

[abmo@novonordisk.com](mailto:abmo@novonordisk.com)

**Liz Skrbkova (US)**

+1 609 917 0632

[lzsk@novonordisk.com](mailto:lzsk@novonordisk.com)

### Investors:

**Daniel Muusmann Bohsen**

+45 3075 2175

[dabo@novonordisk.com](mailto:dabo@novonordisk.com)

**Frederik Taylor Pitter**

+45 3075 8259

[fptra@novonordisk.com](mailto:fptra@novonordisk.com)

**David Heiberg Landsted**

+45 3077 6915

[dhel@novonordisk.com](mailto:dhel@novonordisk.com)

**Mark Joseph Root (US)**

+1 848 213 3219

[mjhr@novonordisk.com](mailto:mjhr@novonordisk.com)

**Sina Meyer**

+45 3079 6656

[azey@novonordisk.com](mailto:azey@novonordisk.com)